The purpose of this program is to support research activities that expand the knowledge base related to complex products and formulation development, analysis, and manufacturing control to advance risk-based quality assessment of new and generic drug products.
We will also consider biological
products relevant to CDER (e.g., monoclonal antibodies and therapeutic proteins) for this announcement.